Fiche centre
TG Therapeutics Investigational Trial Site
Warsaw — Poland
Essais liés4clinical trials
VilleWarsawlocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07220252
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ublituximab | SEP | Phase 2 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | RECRUITING |
| Ublituximab | SEP | Phase 2/3 | NCT07220252 | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT05877963 | ENHANCE — Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |